Surveillance of multi-drug resistant pathogens in two Romanian university hospitals
AbstractHospital acquired infections and bacterial multi-drug resistance (MDR) involve high costs, difficult to manage in medical systems with limited resources. This study, part of the PNCDII 42121/2008 national research project, proposed the investigation of multidrug-resistant bacteria prevalence, concurrent with costs evaluation in two intensive care units (ICUs) from Timisoara university hospitals: Emergency Clinical County Hospital (ECCH) and Institute of Cardiovascular Diseases (ICD). During January-October 2010, we performed a surveillance focused on the following major exponents: Meticillin-resistant Staphylococcus aureus (MRSA), extended spectrum beta-lactamase (ESBL) producing enterobacteria and carbapenem-resistant non-fermentative Gram negative bacilli, with duplicates and colonisation germs exclusion. Selected germs identification and phenotyping were performed with the help of automatic VITEK 2 compact system, using VITEK 2 GP/GN identification cards and AST cards for antimicrobial sensitivity tests. We also performed Hodge tests for ESBL producing carbapenem resistant enterobacteria. At ECCH we isolated 534 bacterial strains, with a 35,44% prevalence for MRSA, 37,32% ESBL enterobacteria and 43,94% carbapenem-resistant nonfermenters. From 73 strains isolated from ICD, the MRSA prevalence was 8,00%, respectively 23,33% ESBL enterobacteria and 11,11% carbapenem-resistant non-fermentatives. The average number of antimicrobial treatment days/MDR infectious episode was 9.11days in ECCH/29.57days in ICD, with an average hospitalisation cost of 3,657.35 €/patient in ECCH/3,780.87 €/patient in ICD. As a conclusion, the study established high prevalence rates of Gram negative bacteria, especially of carbapenem-resistant nonfermenters and evaluated the burden produced on our sanitary sistem, by infections with MDR bacteria.
From Around the Globe
Copyright conditions: Copyright on any research article in the International Journal of Infection Control (IJIC) is retained by the author(s). Authors grant IJIC permission to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. IJIC conforms to the Creative Commons Attribution License (http://creativecommons.org) as terms and conditions of publishing research articles. In summary, anyone is free: • to copy, distribute, and display the work; • to make derivative works; • to make commercial use of the work; as long as: • the original author must be given credit; • for any reuse or distribution, it must be made clear to others what the license terms of this work are; • any of these conditions can be waived if the authors gives permission. Statutory fair use and other rights are in no way affected by the above. Authors' certification: In submitting a manuscript to IJIC, authors are requested to certify that: • They are authorized by their co-authors to enter into these arrangements. • They warrant, on behalf of themselves and their co-authors, that: o the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights; o they are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to IJIC are not in breach of any other obligation. If the law requires that the article be published in the public domain, they will notify IJIC at the time of submission; o the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy; o they have taken due care to ensure the integrity of the article.